Taizhou, China

Libo Ruan

This inventor holds 1 USPTO granted patent and 2 EPO patents. Top assignee: Zhejiang Hisoar Pharmaceutical Co., Ltd.. Active years: 2015.


% Patents Active = 100.0

 

Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2015

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Libo Ruan: Innovator in Pharmaceutical Chemistry

Introduction

Libo Ruan is a notable inventor based in Taizhou, China. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the synthesis of important medicinal compounds. His work has implications for the development of treatments for various health conditions.

Latest Patents

Libo Ruan holds a patent for "Intermediates of sitagliptin and preparation process thereof." This patent discloses intermediates of Sitagliptin, a preparation process thereof, and a process for synthesizing Sitagliptin using these intermediates. Sitagliptin is synthesized by utilizing chiral amino compounds as raw materials, which eliminates the need to build a chiral center through chiral asymmetric catalytic hydrogenation, thus avoiding high-pressure hydrogenation.

Career Highlights

Libo Ruan is currently associated with Zhejiang Hisoar Pharmaceutical Co., Ltd. His innovative approach to synthesizing Sitagliptin has positioned him as a key figure in the pharmaceutical industry. His work not only enhances the efficiency of drug production but also contributes to the accessibility of essential medications.

Collaborations

Some of his coworkers include Xianhua Pan and Weijin Li, who collaborate with him in various research and development projects. Their combined expertise fosters a productive environment for innovation in pharmaceutical chemistry.

Conclusion

Libo Ruan's contributions to the field of pharmaceutical chemistry, particularly through his patent on Sitagliptin intermediates, highlight his role as an influential inventor. His work continues to impact the development of effective treatments in the pharmaceutical industry.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…